Also found in: Wikipedia.
DUSADeputy Under Secretary of the Army
DUSADépartement Universitaire des Sciences d'Agen (French: Science Department University of Agen)
DUSADélégation aux Usagers et aux Simplifications Administratives (French: Delegation to Users and Administrative Simplifications)
DUSADundee University Students' Association (Scotland)
DUSADeakin University Student Association
DUSADaughters of the United States Army (West Point, NY)
DUSADesignated Unclassified Subject Area
DUSADurham University Speleological Association (Durham, England, UK)
References in periodicals archive ?
4% of DUSA's shares were validly tendered and DUSA stockholders will receive USD8.
4% of DUSAa[euro](tm)s shares were validly tendered and DUSA stockholders will receive USD8.
76 % Industries, the country's largest drug maker by market value, inked a pact to acquire US-based DUSA Pharmaceuticals for around USD 230 million (Rs 1,250 crore).
DUSA also wishes to clarify that while negotiations with PhotoCure and Galderma are on-going and progress is being made, there is no certainty if, or when, a settlement will be reached regarding the parties' patent dispute.
Under the terms of the transaction, DUSA shareholders will receive only $8.
Wilmington, Massachusetts-based DUSA develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada and Korea.
If you are a shareholder of DUSA, if you have information or would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G.
If you own common stock in DUSA and wish to obtain additional information and protect your investments free of charge, please visit us at www.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company's board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of DUSA.
On November 8, 2012, DUSA announced that it had entered into a definitive agreement to be acquired by Sun Pharma in an all cash deal valued at approximately $230 million.
The DUSA sale investigation centers on whether DUSA's shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues DUSA's stock, and whether DUSA's board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal.
Under the terms of the transaction, DUSA shareholders will receive $8 in cash for each share of DUSA stock they own, for a total transaction value of approximately $230 million.